Amneal Posts Second Guidance Raise Of The Year Ahead Of Q3 Earnings Report

Firm Anticipates Almost $2.5bn In Net Revenue For The Year

Amneal has raised its 2023 guidance yet again as company performance remained strong across Q3.

Hands holding pile of coins
Amneal anticipates annual net revenue between $2.37bn and $2.42bn • Source: Shutterstock

Amneal Pharmaceuticals, Inc. has posted an additional raise to its annual guidance after Q3 saw the firm experience double-digit revenue and adjusted EBITDA growth. The company now anticipates annual net revenue between $2.37bn to $2.42bn, compared to Q2’s forecast of $2.3bn to $2.4bn.

Earlier this year Amneal had already raised its guidance by $50m following a successful Q2, as its bevacizumab biosimilar exceeded...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business